EU/3/16/1724: Orphan designation for the treatment of systemic sclerosis
nintedanib
Table of contents
Overview
Please note that this product was withdrawn from the Community register of designated orphan medicinal products in May 2020 on request of the of the marketing authorisation holder at the time of the granting of a change to the terms of the marketing authorisation.
On 29 August 2016, orphan designation (EU/3/16/1724) was granted by the European Commission to Boehringer Ingelheim International GmbH, Germany, for nintedanib for the treatment of systemic sclerosis.
Nintedanib for treatment of systemic sclerosis has been authorised in the EU as Ofev 17 April 2020.
Key facts
Active substance |
nintedanib
|
Medicine name |
Ofev
|
Intended use |
Treatment of systemic sclerosis
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/16/1724
|
Date of designation |
29/08/2016
|
Sponsor |
Boehringer Ingelheim International GmbH
Binger Strasse 173 D-55216 Ingelheim am Rhein Germany Tel. +49 61 32770 Fax +49 61 32720 E-mail: info@boehringer-ingelheim.de |
Review of designation
Please note that this product was withdrawn from the Community register of designated orphan medicinal products in May 2020 on request of the of the marketing authorisation holder at the time of the granting of a change to the terms of the marketing authorisation.
The Committee for Orphan Medicinal Products reviewed the orphan designation of Ofev at the time of change to the terms of the marketing authorisation, and confirmed that the orphan designation should be maintained.
More information is available in the
orphan medicine assessment report
.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: